Trials / Completed
CompletedNCT00444743
Phase 2 Study of MM-093 to Treat Patients With Uveitis
A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe uveitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-093 | 60 mg, administered subcutaneously, weekly |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-11-01
- First posted
- 2007-03-08
- Last updated
- 2008-12-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00444743. Inclusion in this directory is not an endorsement.